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Abstract We investigated the expression of angiotensin II type
1 receptor (AT1) in pancreatic cancer. Both AT1 mRNA and
protein were expressed in human pancreatic cancer tissues and
cell lines. Binding assays showed that pancreatic cancer cells
have specific binding sites for angiotensin II and that binding
could be eliminated by treatment with a selective AT1 antagonist
in a dose-dependent fashion. Surprisingly, the growth of cancer
cells was significantly suppressed by treatment with antagonist,
also in a dose-dependent manner. These observations suggest
AT1 plays an important role in pancreatic cancer growth.
Furthermore, ligand-induced inhibition of AT1 may be a useful
therapeutic strategy. ß 2001 Published by Elsevier Science
B.V. on behalf of the Federation of European Biochemical So-
cieties.
Key words: Angiotensin II; Pancreatic cancer; Angiotensin II
type 1 receptor; Angiotensin II type 1 receptor antagonist
1. Introduction
Pancreatic cancer is the ¢fth leading cause of cancer deaths
in Japan, and its overall 5-year survival rate is only 9.3% [1].
In many patients su¡ering from pancreatic cancer, invasions
to surrounding organs and hematogenous metastasis are al-
ready present at the time of diagnosis. Because there is no
useful therapy in pancreatic cancer except for curative oper-
ation, late diagnosis and the aggressive nature of pancreatic
cancer result in a poor survival rate. To improve the prognosis
of pancreatic cancer, it is extremely important to resolve its
growth mechanism.
Angiotensin II (Ang-II) is the main e¡ector peptide of the
renin^angiotensin system and it exerts a variety of actions on
the cardiovascular and renal systems. Recently, two main sub-
types of Ang-II receptors have been found using selective
antagonists and named type 1 receptor (AT1) and type 2
receptor (AT2) [2,3]. Growth-modulating e¡ects of these re-
ceptors were reported in coronary endothelial cells and vas-
cular smooth muscle cells [4,5], where AT1 caused cell prolif-
eration, whereas AT2 acted in an anti-proliferative manner.
Expression pro¢les of these receptors in the cardiovascular
system demonstrated that AT1 was dominantly expressed in
physiological conditions, but AT2 was expressed in some mor-
bid conditions, such as cardiac hypertrophy and myocardial
infarction [6,7].
Despite the fact that the role of Ang-II and its receptors has
been well discussed in the cardiovascular ¢eld, few reports can
be found about the expression of AT1 in cancer cells [8^11],
and no reports were found about the relation between AT1
and the growth of cancer cells. In the present study, we exam-
ined the expression of AT1 in human pancreatic cancer, and
are the ¢rst to demonstrate that AT1 regulates the growth of
pancreatic cancer.
2. Materials and methods
2.1. Cell culture and tissue specimens
The pancreatic cancer cell lines used in this study were PANC-1,
MIA PaCa-2, and Capan-2, and they were purchased from the Amer-
ican Type Culture Collection. Cells were maintained in Dulbecco’s
modi¢ed Eagle’s medium (DMEM; Gibco-BRL, USA) supplemented
with 10% fetal bovine serum (FBS; Iwaki, Japan), 10 U/ml penicillin^
streptomycin (Gibco-BRL, USA), and incubated in a humidi¢ed at-
mosphere of 5% CO2 and 95% air at 37‡C. A selective antagonist of
AT1, L-158,809 (kindly supplied by Merck and Co., USA), was dis-
solved in dimethyl sulfoxide and applied to cells at a concentration of
0.1% of the medium volume. Fresh pancreatic cancer tissues and
normal pancreatic tissues were surgically obtained after obtaining in-
formed consent from patients. All pancreatic cancers were of ductal
origin. For RNA puri¢cation, specimens were immediately frozen in
liquid nitrogen, and stored at 380‡C until extraction.
2.2. RNA puri¢cation and RT-PCR
For RNA puri¢cation, frozen tissues were homogenized using a
microhomogenizer (Cosmo Biol. Co., Ltd., Japan), and total RNA
from these tissues and cell lines was prepared using the Fast RNA
Kit-Green1 (Bio-101, USA). The primer sequences of AT1 and
G3PDH were as follows: 5P-AGATGATTGTCCCAAAGCTG-3P
(forward), and 5P-GCTTCTTGGTGGATGAGCTT-3P (reverse), for
human AT1; and 5P-TCCACCACCCTGTTGCTGTA-3P (forward),
and 5P-ACCACAGTCCATGCCATCAC-3P (reverse), for G3PDH.
The expected sizes of the PCR products for AT1 and G3PDH are
1010 bp and 450 bp, respectively. A 200 ng quantity of total RNA
was reverse transcribed with Moloney murine leukemia virus reverse
transcriptase (Toyobo Co., Ltd., Japan) at 42‡C for 30 min in a 20 Wl
mixture in the presence of 25 pmol of oligo(dT)20 primer. A 20 Wl
amount of the reverse transcribed mixture was subjected to PCR in a
100 Wl mixture in the presence of 1 U of KOD Dash1 (Toyobo Co.,
Ltd., Japan) and 20 pmol of each primer. PCR was performed for 35
cycles (denaturation at 98‡C for 15 s, annealing at 60‡C for 3 s and
extension at 74‡C for 45 s). PCR products (10 Wl) were separated in
1.5% agarose gels, stained with SYBR-green (Eugene, USA), and vi-
sualized under ultraviolet light.
2.3. Western blot analysis
Lysates were prepared by treating cells with a lysis bu¡er consisting
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of 125 mM Tris-bu¡ered saline (pH 6.8), 2% sodium dodecyl sulfate
(SDS), 5% glycerol, 0.003% BPB and 1% L-mercaptoethanol. SDS^
PAGE was performed on 10% polyacrylamide gels, and the resolved
proteins were transferred to a nitrocellulose membrane. The mem-
brane was blocked with horse serum and incubated with an anti-
AT1 rabbit polyclonal antibody (2 Wg/ml; sc-1173, Santa Cruz Bio-
technology, USA). After incubating with horseradish peroxidase-con-
jugated anti-rabbit IgG (Santa Cruz Biotechnology, USA), the mem-
brane was developed by Western Blot Chemiluminescence Reagent
Plus (NEN1 Life Science Products, USA), and exposed to autora-
diography ¢lm (NEN1 Life Science Products, USA). For neutraliza-
tion of AT1 antibody, we reacted antibody with a 10-fold excess of
peptide antigen (sc-1173P, Santa Cruz Biotechnology, USA).
2.4. Immunocytochemistry and immunohistochemistry
For immunocytochemistry, pancreatic cancer cells were grown on
glass coverslips and the cells were ¢xed with 4% paraformaldehyde in
phosphate-bu¡ered saline (PBS) for 20 min. The cells were washed
and incubated for 1 h with the primary antibody at a 1:250 dilution.
After washing with PBS, they were incubated for 1 h with FITC-
labeled anti-rabbit IgG. The coverslips were washed with PBS,
mounted on glass slides and viewed with a confocal laser scanning
microscope (TCS-NT, Leica-laser-technik GmbH, Germany). Immu-
nostaining of surgically resected tissues was performed on formalin-
¢xed, para⁄n-embedded tissues using a standard avidin^biotin^per-
oxidase technique. After treatment by microwaves, endogenous per-
oxidase activity was suppressed with 0.3% hydrogen peroxide and
methanol. The sections were sequentially treated with 5% normal
goat serum, primary antibodies (1:250 dilution), biotinylated anti-rab-
bit IgG, and an avidin^biotin^peroxidase complex (Vector Laborato-
ries, Burlingame, CA, USA). Diaminobenzidine was used as a chrom-
ogen in the presence of hydrogen peroxide. For non-immune staining,
we used PBS instead of the primary antibody. Hematoxylin was used
as a counterstain. Study specimens were evaluated independently by
two investigators (Y.F. and T.S.) and reviewed by a pathologist.
2.5. Receptor binding assay
Binding assays were performed on 96-well plates containing 1U104
cells per well. Before the binding assay, the medium was changed to
DMEM containing 0.1% FBS for 24 h. Binding was carried out for 1 h
at 4‡C in 30 Wl of binding medium (Gibco-BRL, USA) containing
0.5% bovine serum albumin with [125I]Ang-II (Amersham Pharmacia
Biotech Japan, Tokyo, Japan), in the presence of unlabeled Ang-II
(Sigma-Aldrich Co., USA) or L-158,809. After incubation, cells were
rinsed with binding medium three times at 4‡C. The cell layer was
then lysed in NaOH (0.1 N), and radioactivity was counted in a
Q-counter (Aloka, USA). Each treatment was performed in triplicate.
2.6. Cell proliferation assay
Cells were plated on 96-well plates in DMEM containing 10% FBS
for 12 h. The medium was then changed to DMEM containing 0.1%
FBS for 24 h. In proliferation assays, the cells were exposed to di¡er-
ent concentrations of L-158,809 or vehicle for 24 h. All proliferation
assays were examined using a cell counting kit (Dojindo, Japan), and
cell proliferation was quanti¢ed using a plate analyzer (Toyo Sokki,
Japan). Each treatment was performed in triplicate.
2.7. Statistical analysis
Statistical analysis was performed using Sche¡e¤’s F test. Results are
presented as the mean þ S.E.M. of triplicate samples from at least two
independent experiments. A probability level of P6 0.05 was consid-
ered statistically signi¢cant.
3. Results and discussion
3.1. AT1 expression in pancreatic cancer tissues
We ¢rst examined the expression of AT1 in human pancre-
atic tissues. RT-PCR demonstrated that AT1 mRNA was ex-
pressed in six of eight pancreatic cancer tissues (Fig. 1A). In
contrast, it was expressed in only one of four normal pancre-
atic tissues (Fig. 1B). Moreover, immunohistochemical stain-
ing revealed that AT1 protein was also expressed in 27 out of
50 cases of pancreatic cancer (Fig. 1C). On the other hand,
AT1 protein was negligibly expressed in normal pancreatic
tissues, and only observed in islands of Langerhans in some
cases (Fig. 1E). These ¢ndings suggested that AT1 was over-
expressed in pancreatic cancer.
3.2. AT1 expression in pancreatic cancer cells
We next investigated the role of AT1 in pancreatic cancer
cell lines. As shown in Fig. 2A, the 1010-bp PCR products
corresponding to AT1 mRNA were observed in all cell lines.
Fig. 1. Expression of AT1 mRNA and protein in pancreatic tissues.
A: Total RNA from pancreatic cancer tissues was extracted and
ampli¢ed by RT-PCR. The arrowhead at the 1010-bp band indi-
cates the position of the AT1 mRNA. The arrowhead at the 450-bp
band indicates the position of G3PDH. Lanes are as follows: lane
1, molecular marker; lanes 2^9, pancreatic carcinoma tissues. B:
Total RNA from normal pancreatic tissues was extracted and am-
pli¢ed by RT-PCR. Lanes are as follows: lane 1, molecular marker;
lanes 2^5, normal pancreatic tissue. C: Expression of AT1. D: Its
non-immune staining in human pancreatic carcinoma tissue by im-
munohistochemistry. E: Expression of AT1 in normal pancreas tis-
sue by immunohistochemistry.
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To elucidate the post-transcriptional regulation of AT1 we
next performed Western blot analysis using a speci¢c anti-
body. The results demonstrated that 44-kDa proteins were
found in all three cell lines, and that those bands disappeared
upon treatment with the AT1 blocking peptide (Fig. 2B). We
then examined the localization of AT1 protein in these cells
using immuno£uorescence staining. Immunoreactive green
signals were detected in the cell membrane and cytoplasm of
these cells (Fig. 2C). No nuclear staining was observed. It is
reported that the AT1s are internalized within the cell and
recycled to the cell surface [12]. The cytoplasmic localization
we observed may contribute to the receptor internalization. In
addition, these cellular distributions may depend on the extent
of receptor occupancy.
3.3. Receptor binding assay
We next examined the binding function between AT1 in
cancer cells and Ang-II. Because the most common type of
pancreatic cancer is well-di¡erentiated, we chose to use Ca-
pan-2 cells in this binding assay. Exogenous iodinated Ang-II
was able to saturate Ang-II receptors on Capan-2 cells (Fig.
3A). The speci¢c binding was calculated by subtracting non-
speci¢c binding from total binding. Scatchard plot analysis
demonstrated that Capan-2 cell have a speci¢c binding site
for Ang-II with an equilibrium binding constant (Kd) value
of 6.1 nM and a maximum binding capacity (Bmax) of 9 fmol/
106 cells (data not shown). Displacement experiments were
performed on cultured Capan-2 cells to classify the kinds of
Fig. 2. Expression of AT1 mRNA and protein in three pancreatic
carcinoma cell lines. A: Total RNA from pancreatic carcinoma cells
was extracted and ampli¢ed by RT-PCR. The arrowhead at the
1010-bp band indicates the position of the AT1 mRNA. The arrow-
head at the 450-bp band indicates the position of G3PDH. B: Total
cell lysates were subjected to SDS^PAGE, transferred to a nitrocel-
lulose membrane and incubated with an AT1-speci¢c antibody. In
A and B, lanes are as follows: lane 1, molecular marker; lane 2,
PANC-1; lane 3, MIA PaCa-2; lane 4, Capan-2; lane 5, PANC-1
+blocking peptide. C: The expression of the AT1 receptor was dem-
onstrated by immunocytochemistry. Cells were grown on coverslips,
¢xed and stained with a FITC-labeled anti-AT1 receptor antibody.
Fig. 3. Binding assay and L-158,809-induced growth suppression on
pancreatic carcinoma cell lines. A: The graph shows saturation
binding of [125I]Ang-II to Capan-2 cells. Speci¢c binding (b) was
calculated by subtracting the non-speci¢c binding (a) from the total
binding (7). B: A displacement experiment against the binding of
[125I]Ang-II on cultured Capan-2 cells was performed. Binding was
carried out for 1 h at 4‡C in binding medium with [125I]Ang-II and
L-158,809. The speci¢c binding of [125I]Ang-II was dose-dependently
competed with L-158,809. P values are a comparison between the
untreated group and the treated group (*P6 0.05). C: Cells were
exposed to di¡erent concentrations of L-158,809. Each point repre-
sents a relative growth ratio to control. L-158,809 showed growth
inhibition in a dose-dependent manner. PANC-1 (a), MIA PaCa-2
(E), Capan-2 (7).
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receptor. The speci¢c binding of [125I]Ang-II was dose-de-
pendently competed with L-158,809 (Fig. 3B). Ang-II binding
to cells was suppressed by 74.1% when the dose of inhibitor
used was up to 1037 M. These data show that most of the
Ang-II binding sites on Capan-2 cells were AT1s.
3.4. Growth inhibition by AT1-selective antagonist
Since pancreatic cancer cells expressed AT1, which was able
to bind natural Ang-II, we next examined the e¡ects of AT1
on the growth of pancreatic cancer cells. According to the
result of the binding assay, we selected the concentrations of
L-158,809 in the range from 1039 to 1036 M. But cell growth
was not a¡ected in these ranges. In the range of 0^100 WM, L-
158,809 inhibited growth in a dose-dependent manner (Fig.
3C). The speci¢c IC50 values for the reduction in cell prolif-
eration were calculated using each dose^response curve and
were determined to be approximately 85 WM in PANC-1 cells,
30 WM in MIA PaCa-2 cells, and 120 WM in Capan-2 cells.
These results suggested that the e¡ect of L-158,809 on cell
growth was dependent on cellular di¡erentiation. And still
more, there is a discrepancy in concentration between binding
and growth assays. One of the possible reasons for this dis-
crepancy is that the pancreatic cancer cells used in this study
(Capan-2) may have not enough AT1 receptors for L-158,809
to inhibit its growth. Judging from this possibility, it may be
reasonable that the higher dose of L-158,809 is necessary to
inhibit the growth of Capan-2 cells. In this point of view,
further studies will be needed to understand the signal path-
ways for cell proliferation in Capan-2.
To con¢rm that the growth inhibition did not interfere with
cell viability, the trypan blue exclusion assay and light micro-
scopic observation were performed. The results demonstrated
that the proportion of viable cells and cell morphology were
not in£uenced, suggesting that the anti-mitotic activity of L-
158,809 is not due to the cytotoxicity of this drug.
It has been suggested that there are some important factors
that promote the growth of pancreatic cancer. Gastrin, secre-
tin, cholecystokinin, and epidermal growth factor have been
reported to promote the proliferation of pancreatic cancer
cells [13,14]. Recently, we have also reported that phospholi-
pase A2 stimulates the proliferation of pancreatic cancer cells
[15]. To the best of our knowledge, there have been no reports
investigating the relationship between the angiotensin receptor
and cancer growth. In the present study, we have demon-
strated that a selective antagonist of AT1 suppresses the
growth of human pancreatic cancer. A previous study re-
ported that angiotensin-converting enzyme (ACE) inhibitors
exhibit antimitotic activity in pancreatic cancer cells [16]. Fur-
thermore, a clinical retrospective study of the e¡ects of ACE
inhibitors on cancer has been reported [17]. Studies by Lever
et al. indicated that the incidence of cancer was reduced by
continuous intake of an ACE inhibitor, although the anti-
tumorigenic mechanisms were not determined su⁄ciently.
Judging from these reports and the results presented here, it
is suggested that Ang-II and AT1 play an important role in
maintaining the growth of human pancreatic cancer.
In other neoplastic cells and tissues, it was reported that
two subtypes of Ang-II receptors are present in various pro-
portions. For instance, AT1s were detected in normal and
diseased human breast tissues [10] but most of the Ang-II
receptors detected in colorectal cancer cells were AT2 recep-
tors [11]. In the present study we did not examine the other
type of receptors for Ang-II. The results of binding assays
showed that the speci¢c antagonist of AT1 was not able to
completely displace Ang-II from all binding sites. Therefore,
further studies will be needed to de¢ne the other type of
receptor on pancreatic cancer cells.
In conclusion, this is the ¢rst study to investigate the ex-
pression of AT1 in human pancreatic cancer and to explore
the e¡ects of an AT1 antagonist on this cancer. Our data
suggest that AT1 is a target for the prevention of pancreatic
cancer. Further studies to determine the mechanisms associ-
ated with growth inhibition by the AT1 antagonist are needed
to understand this process.
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